<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">K Vermaelen</style></author><author><style face="normal" font="default" size="100%">A Waeytens</style></author><author><style face="normal" font="default" size="100%">O Kholmanskikh</style></author><author><style face="normal" font="default" size="100%">Marc Van den Bulcke</style></author><author><style face="normal" font="default" size="100%">Els Van Valckenborgh</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Perspectives on the integration of Immuno-Oncology Biomarkers and drugs in a Health Care setting.</style></title><secondary-title><style face="normal" font="default" size="100%">Semin Cancer Biol</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Antineoplastic Agents</style></keyword><keyword><style  face="normal" font="default" size="100%">Biomarkers, Tumor</style></keyword><keyword><style  face="normal" font="default" size="100%">Delivery of Health Care</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunotherapy</style></keyword><keyword><style  face="normal" font="default" size="100%">Medical Oncology</style></keyword><keyword><style  face="normal" font="default" size="100%">Neoplasms</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2018</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2018 10</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">52</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Immunotherapies, specifically checkpoint inhibitors, are becoming an important component in cancer care with the most application now in melanoma and lung cancer patients. Some drawbacks that converge with this new evolution are the rather low response rates to these drugs and their high cost with a significant economic impact on the health care system. These major challenges can likely be circumvented by implementing a &quot;personalized immuno-oncology&quot; approach to accomplish a selection of optimal responders based on biomarkers. In this paper we first discuss the legal framework for the development of valuable in vitro diagnostics. Based on a case study in lung cancer, the clinical validity and utility requirements of predictive immuno-oncology biomarkers is highlighted and an overview is given on the evolution towards multiplex or omics-based assays together with its challenges and pitfalls. Finally, some initiatives between the public and private sector are pinpointed to sustain the future access to innovative medicines in cancer therapy at a reasonable cost.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">Pt 2</style></issue></record></records></xml>